Eliminating the public health problem of hepatitis B and C in the United States : phase one report /

Saved in:
Bibliographic Details
Imprint:Washington, DC : National Academies Press, [2016]
Description:1 online resource (1 PDF file (xiv, 171 pages)) : illustrations
Language:English
Subject:
Format: E-Resource Book
URL for this record:http://pi.lib.uchicago.edu/1001/cat/bib/11263438
Hidden Bibliographic Details
Other authors / contributors:Buckley, Gillian J., editor.
Strom, Brian L., editor.
National Academies of Sciences, Engineering, and Medicine (U.S.). Committee on a National Strategy for the Elimination of Hepatitis B and C, issuing body.
ISBN:9780309437998
0309437997
9780309438001
0309438004
Digital file characteristics:data file
Notes:Includes bibliographical references.
This activity was supported by Contract No. 10002774 with the US Department of Health and Human Services [Centers for Disease Control and Prevention]. Any opinions, findings, conclusions, or recommendations expressed in this publication do not necessarily reflect the views of any organization or agency that provided support for the project.
Online resource; title from PDF title page (viewed Aug. 3, 2016).
Summary:Hepatitis B and C cause most cases of hepatitis in the United States and the world. The two diseases account for about a million deaths a year and 78 percent of world's hepatocellular carcinoma and more than half of all fatal cirrhosis. In 2013 viral hepatitis, of which hepatitis B virus (HBV) and hepatitis C virus (HCV) are the most common types, surpassed HIV and AIDS to become the seventh leading cause of death worldwide. The world now has the tools to prevent hepatitis B and cure hepatitis C. Perfect vaccination could eradicate HBV, but it would take two generations at least. In the meantime, there is no cure for the millions of people already infected. Conversely, there is no vaccine for HCV, but new direct-acting antivirals can cure 95 percent of chronic infections, though these drugs are unlikely to reach all chronically-infected people anytime soon. This report, the first of two, examines the feasibility of hepatitis B and C elimination in the United States and identifies critical success factors. The phase two report will outline a strategy for meeting the elimination goals discussed in this report.
Other form:Print version: National Academies of Sciences, Engineering, and Medicine (U.S.). Committee on a National Strategy for the Elimination of Hepatitis B and C. Eliminating the public health problem of hepatitis B and C in the United States. Washington, DC : the National Academies Press, [2016] 9780309437998